Physician profile
Javier Reyna
NPI 1780991547
$8,518.98
in general payments reported to CMS, 2019-2025
30 companies · $1,333 in 2025
The $1,333 reported for 2025 was more than what 76% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $606 · 2020: $295 · 2021: $1,137 · 2022: $1,821 · 2023: $1,694 · 2024: $1,634 · 2025: $1,333.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,661.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,661.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,312.30 | 2021-2025 | Azure Xt Dr Mri Surescan, Cobalt Dr Mri Surescan, Closurefast |
| Novartis Pharmaceuticals Corporation | $1,232.15 | 2019-2025 | |
| Pfizer INC. | $837.66 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $813.06 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $635.50 | 2019-2025 | Camzyos, Eliquis |
| Boston Scientific Corporation | $537.82 | 2021-2023 | Watchman Flx |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $464.70 | 2019-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $361.24 | 2023-2025 | Jardiance |
| Edwards Lifesciences Corporation | $331.77 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $327.10 | 2020-2025 | Lokelma, Breztri |
| Merck Sharp & Dohme LLC | $308.39 | 2022-2025 | Verquvo |
| Abbott Laboratories | $296.29 | 2020-2025 | Aveir |
| Bayer Healthcare Pharmaceuticals INC. | $262.28 | 2021-2025 | |
| Impulse Dynamics (USA) INC. | $216.32 | 2023-2024 | Optimizer, Optimizer |
| Novo Nordisk INC | $100.17 | 2023-2025 | Ozempic, Rybelsus |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $78.85 | 2023-2024 | Inpefa |
| Scpharmaceuticals INC. | $71.30 | 2024-2025 | |
| Kestra Medical Technology Services, INC. | $59.46 | 2025 | Assure Wcd |
| Amgen INC. | $47.99 | 2022 | |
| Sanofi-Aventis U.S. LLC | $41.07 | 2023-2024 | |
| Kiniksa Pharmaceuticals International, Plc | $35.75 | 2024 | Arcalyst |
| Esperion Therapeutics, INC. | $35.55 | 2024-2025 | Nexletol |
| Atricure, INC. | $28.18 | 2023 | |
| Inspire Medical Systems, INC. | $23.32 | 2025 | Inspire |
| Amarin Pharma, INC. | $22.52 | 2021 | |
| Kiniksa Pharmaceuticals, LTD. | $20.27 | 2023 | Arcalyst |
| Vital Connect, INC | $17.97 | 2025 | Vitalpatch Rtm |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Javier Reyna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.